Omega Ophthalmics: Funding, Investors & Team (Oct 2026)
Cataract surgery is the single most common procedure performed in the United States annually. Despite technological advancements in both surgical instrumentation and intraocular lens design, approximately 50% of patients are still unable to see well without glasses after surgery. Omega Ophthalmics has developed a new, proprietary lens that will increase the number of “glasses free” post-surgery patients to over 90% by reducing the variables during surgery, revolutionizing a market that has not seen positive, disruptive change in over sixty years. Since the global intraocular lens market has steadily grown and is currently projected to reach $4.3 billion by 2017, the Omega Gemini Refractive Capsule is well-positioned to become the new standard lens for cataract surgery. The Omega Gemini Refractive Capsule is an investigational device and is not approved for use in the United States.
Omega Ophthalmics has raised $7.3M across 2 funding rounds on record, the most recent a Series A of $7.0M announced in Aug 2026.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Omega Ophthalmics Company Profile and Key Stats
Latest funding round on record: Aug 2026.
Omega Ophthalmics Funding Rounds
Omega Ophthalmics raised $320k in an undisclosed round announced in Jan 2026.
7 months later, a Series A of $7.0M was announced in Aug 2026.
Omega Ophthalmics Founders and Leadership Team
Contact details for the Omega Ophthalmics team: 1 has a LinkedIn profile.
Start 14-day free trial →Omega Ophthalmics Funding Compared to Other Biotechnology Startups
Omega Ophthalmics' latest round of $7.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Omega Ophthalmics in Biotechnology and Lexington
Companies Similar to Omega Ophthalmics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Omega Ophthalmics Funding FAQs
What does Omega Ophthalmics do?
Cataract surgery is the single most common procedure performed in the United States annually. Despite technological advancements in both surgical instrumentation and intraocular lens design, approximately 50% of patients are still unable to see well without glasses after surgery. Omega Ophthalmics has developed a new, proprietary lens that will increase the number of “glasses free” post-surgery patients to over 90% by reducing the variables during surgery, revolutionizing a market that has not seen positive, disruptive change in over sixty years. Since the global intraocular lens market has steadily grown and is currently projected to reach $4.3 billion by 2017, the Omega Gemini Refractive Capsule is well-positioned to become the new standard lens for cataract surgery. The Omega Gemini Refractive Capsule is an investigational device and is not approved for use in the United States.
How much funding has Omega Ophthalmics raised?
Omega Ophthalmics has raised $7.3M across 2 rounds on record. The most recent is a Series A of $7.0M announced in Aug 2026.
When did Omega Ophthalmics last raise funding?
Omega Ophthalmics' most recent funding round on record is a Series A of $7.0M, announced in Aug 2026.
Who founded Omega Ophthalmics?
FundedIQ lists Rick Ifland (Founder) at Omega Ophthalmics.
Where is Omega Ophthalmics headquartered?
Omega Ophthalmics is based in Lexington, Kentucky, United States.
How many employees does Omega Ophthalmics have?
Omega Ophthalmics is in the 51-100 employee band.
When was Omega Ophthalmics founded?
Omega Ophthalmics was founded in 2013.
How does Omega Ophthalmics' funding compare to other Biotechnology startups?
Omega Ophthalmics' latest round of $7.0M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Omega Ophthalmics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Omega Ophthalmics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.